Abstract Details

Title Characteristics and clinical outcomes of underserved minority patients with multiple sclerosis treated with peginterferon beta-1a or intramuscular interferon beta-1a in MS PATHS

Topic Multiple Sclerosis

Presentation(s) MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 169

Objective Provide real-world data on baseline characteristics and clinical outcomes in underserved minority patients with multiple sclerosis (MS) on interferon beta-1a therapy.

Background Data on minority patients with MS are limited. This exploratory, descriptive analysis provides real-world data on minority MS patients treated with interferon beta-1a in MS PATHS, an international network of MS centers.

Design/Methods This analysis includes MS PATHS patients treated with peginterferon beta-1a or intramuscular interferon beta-1a at baseline or a follow-up visit. Baseline visit characteristics and on-treatment annualized relapse rates (ARRs) were assessed. P values were calculated based on a Wilcoxon signed-rank test. Baseline comparisons are cross-sectional and follow-up comparisons are longitudinal.

Results In this analysis of 1018 patients, 152 non-White patients, including a subset of 81 Black/African American patients, were compared to 866 White patients, and 29 Hispanic patients were compared to 560 non-Hispanic patients. A greater percentage of Black/African American patients (32.1%) and non-White patients (30.3%) than White patients (15.7%) had ≥2 relapses in the year before treatment initiation, and a greater percentage of Hispanic patients (34.5%) than non-Hispanic patients (18.4%) had ≥2 relapses in the prior year. At treatment start, mean T2 lesion volume was greater in non-White patients (14.13 cm³) and Black/African American patients (12.00 cm³) than White patients (8.77 cm³), and Hispanic patients had a larger mean T2 volume (13.32 cm³) than non-Hispanic patients (8.70 cm³). Compared with the White subgroup, on-treatment ARRs were significantly higher in the Black/African American (1.26 vs 0.64; P=0.00188) and non-White (1.10 vs 0.64; P=0.00125) subgroups, whereas ARRs were comparable in the Hispanic and non-Hispanic subgroups (0.92 vs 0.64; P=0.694).

Conclusions Minority patients had greater baseline disease activity and MRI disease burden, and higher on-treatment ARRs than White/non-Hispanic patients. These results highlight the need for closer observation of MS minority patients to improve treatment outcomes.

Authors/Disclosures
Carrie M. Hersh, DO, MSc, FAAN (Cleveland Clinic Lou Ruvo Center for Brain Health) PRESENTER	Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech_GN41791. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genzyme. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol-Myers Squibb . Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Horizon Therapeutics. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Hersh has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. The institution of Dr. Hersh has received research support from Biogen. The institution of Dr. Hersh has received research support from Novartis. The institution of Dr. Hersh has received research support from Genentech_GN41791. The institution of Dr. Hersh has received research support from PCORI. The institution of Dr. Hersh has received research support from Bristol Myers Squibb.
Kathryn Fitzgerald, PhD (Johns Hopkins University)	Dr. Fitzgerald has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Setpoint Medical. The institution of Dr. Fitzgerald has received research support from NIH. The institution of Dr. Fitzgerald has received research support from National MS Society.
Lana Zhovtis Ryerson, MD, FAAN (Jersey Shore University Medical Center)	Dr. Zhovtis Ryerson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Zhovtis Ryerson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi.
Ellen M. Mowry, MD, FAAN (Johns Hopkins University)	Dr. Mowry has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Octave. Dr. Mowry has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SetPoint. The institution of Dr. Mowry has received research support from Genentech/Roche. The institution of Dr. Mowry has received research support from Biogen. Dr. Mowry has received publishing royalties from a publication relating to health care.
Shirley Liao	Shirley Liao has received personal compensation for serving as an employee of Biogen.
	No disclosure on file
Maria Naylor, PhD	Dr. Naylor has received personal compensation for serving as an employee of Dyne Therapeutics. Dr. Naylor has stock in Biogen. Dr. Naylor has stock in Dyne Therapeutics.

��ɫ��

��ɫ��